Search Results

According to recent study by nova one advisor, the U.S. oncology molecular diagnostics market size was valued at USD 0.85 billion in 2023 and is anticipated to reach around USD 2.74 billion by 2033, growing at a CAGR of 12.41% from 2024 to 2033

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.

Alumis is debuting in an initial public offering Friday on the Nasdaq, though the $250 million IPO is less than its initial targeted raise of $274 million just days ago.

Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists as therapeutic-adjuvants for acute viral diseases and cancer.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the progression of REDWOOD-HCM following the conduct of an interim analysis of data from Cohort 1. REDWOOD-HCM ( R andomized E valuation of D osing W ith CK-274 in O bstructive O utflow D isease in HCM ) is an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic car

RTW Investments, LP, (“RTW”) is pleased to announce Ji Xing Pharmaceuticals (“Ji Xing”), have entered into an exclusive licensing agreement for the development and commercialization of CK-274, a next-generation cardiac myosin inhibitor, in Greater China

Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -274 trial, which showed that Opdivo (nivolumab) significantly improved disease-free survival (DFS) as an adjuvant treatment across all randomized patients with surgically resected,

Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial In an interim analysis, CheckMate -274 met primary endpoints of disease-free survival in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% Opdivo has now demonstrated clinically meaningful efficacy in the adjuvant treatment of